Plastic and nonmetallic article shaping or treating: processes – Encapsulating normally liquid material – Liquid encapsulation utilizing an emulsion or dispersion to...
Reexamination Certificate
2000-01-06
2002-10-08
Lovering, Richard D. (Department: 1712)
Plastic and nonmetallic article shaping or treating: processes
Encapsulating normally liquid material
Liquid encapsulation utilizing an emulsion or dispersion to...
C264S004100, C424S435000, C424S491000, C427S213300, C427S213350, C514S400000, C514S963000
Reexamination Certificate
active
06461545
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to the preparation of solutions containing imidazole derivatives and to the use of those solutions in the preparation of microspheres. The imidazole derivative containing microspheres are effective in treating fungal infections, particularly in mammals. The microspheres facilitate the oral administration of relatively large amounts of the imidazole derivative, with increased bioavailability.
BACKGROUND OF THE INVENTION
Many present systems for delivering active agents to targets are severely limited by biological, chemical, and physical barriers, which are imposed by the environment through which delivery occurs, the environment of the target itself, or the target itself. Delivery is also limited, in many instances, by the chemical nature of the active agent. For example, oral delivery is generally ineffective with active agents that are poorly water-soluble.
The imidazole derivative family of compounds is particularly effective against a broad range of fungal infections such as those caused by
Trichophyton rubrum, Tricophyton mentagrophytes, Epidermophyton floccsum,
and
Candida albicans,
but these compounds are either partially water soluble or insoluble in water. For example, the solubility of itraconazole in water is less than 0.00001 g/ml.
Partially because imidazole derivatives are typically insoluble in water, they are difficult to administer orally. Consequently although imidazole derivatives are frequently prescribed for the treatment of fungal infections, they have been available only in topical preparations or in oral formulations with limited bioavailability.
In recent years, fungal infections, such as those caused by
Candida albicans
in particular have become more prevalent and intractable due to their appearance in immunocompromised patients, such as those infected with Human Immunodeficiency Virus (HIV) or those suffering from Acquired Immunodeficiency Syndrome (AIDS).
For example, U.S. Pat. No. 3,717,655 discloses imidazole derivatives which have antifungal and antibacterial activity. These compounds are almost insoluble in aqueous solutions such as water and are very poorly soluble in polar solvents such as ethanol.
Das et al., U.S. Pat. No. 4,912,124, disclose a solvent system for imidazole derivatives that include mixtures of a polar solvent, a polyhydric alcohol that acts as a solubilizing agent, a nonionic or amphoteric surfactant, and a cosmetic humectant. Solutions containing at least 1 percent by weight of the imidazole derivatives can be formulated using this solvent system. However, these formulations are suitable for external topical use only.
Accordingly, there is a need for orally deliverable forms of imidazole derivative antifungal agents.
SUMMARY OF THE INVENTION
The present invention provides solutions comprising:
(a) at least about 2.5 parts by weight, based upon 100 parts by weight of solution, of a solute having the formula
wherein R, R
1
, and R
2
are independently hydrogen or lower alkyl;
R
3
is hydrogen, methyl or ethyl;
R
4
is hydrogen or methyl
Ar is phenyl, monohalophenyl, dihalophenyl, trihalophenyl, mono(lower alkyl)phenyl, di(lower alkyl)phenyl, lower alkoxyphenyl, or halothienyl;
Ar
1
is phenyl, monohalophenyl, dihalophenyl, trihalophenyl, mono(lower alkyl)phenyl, di(lower alkyl)phenyl, lower alkoxyphenyl, or cyanophenyl; and
n is 1 or 2; and
(b) a solubilizing effective amount of a solvent comprising at least one volatile organic acid solvent.
Imidazole derivative microspheres are also provided. These microspheres comprise:
(a) an imidazole derivative active agent having the formula
wherein
R, R
1
, and R
2
are independently hydrogen or lower alkyl;
R
3
is hydrogen, methyl or ethyl;
R
4
is hydrogen or methyl
Ar is phenyl, monohalophenyl, dihalophenyl, trihalophenyl, mono(lower alkyl)phenyl, di(lower alkyl)phenyl, lower alkoxyphenyl, or halothienyl;
Ar
1
is phenyl, monohalophenyl, dihalophenyl, trihalophenyl, mono (lower alkyl)phenyl, di(lower alkyl)phenyl, lower alkoxyphenyl, or cyanophenyl; and
n is 1 or 2; and
(b) a microsphere forming carrier selected from the group consisting of
(i) a proteinoid;
(ii) an acylated amino acid, poly amino acid, or a salt thereof;
(iii) an sulfonated amino acid, poly amino acid, or a salt thereof;
(iv) a protein or a salt thereof;
(v) an enteric coating material; or
(vi) any combination thereof.
Also contemplated by the present invention is a method for preparing these microspheres. The method comprises:
(A) nebulizing a solution comprising
(a) an imidazole active agent having the formula
wherein
R, R
1
, and R
2
are independently hydrogen or lower alkyl;
R
3
is hydrogen, methyl or ethyl;
R
4
is hydrogen or methyl
Ar is phenyl, monohalophenyl, dihalophenyl, trihalophenyl, mono(lower alkyl)phenyl, di(lower alkyl)phenyl,. lower alkoxyphenyl, or halothienyl;
Ar
1
is phenyl, monohalophenyl, dihalophenyl, trihalophenyl, mono(lower alkyl)phenyl, di(lower alkyl)phenyl, lower alkoxyphenyl, or cyanophenyl; and
n is 1 or 2;
(b) an active agent and carrier solubilizing effective amount of a solvent comprising an aqueous solution of at least one volatile organic solvent; and wherein the volume:volume ratio of acid to water in said carrier solution is at least about 3:7, and
(c) microsphere forming a carrier selected from the group consisting of
(i) a proteinoid;
(ii) an acylated amino acid or poly amino acid or a salt thereof;
(iii) an sulfonated amino acid or poly amino acid or a salt thereof;
(iv) a protein or a salt thereof;
(v) an enteric coating material, or
(vi) any combination thereof; and
(B) decreasing said ratio to less than about 3:7, to yield said microspheres. Alternatively, the active agent and the carrier can be solubilized in separate solutions. The separate solutions can be nebulized together and the acid to water ratio then decreased as above.
Methods for the oral administration of imidazole derivatives are also contemplated wherein the microsphere compositions above are orally administered to an animal in need of this treatment.
REFERENCES:
patent: 2671451 (1954-03-01), Bolger
patent: 2828206 (1958-03-01), Rosenberg
patent: 2862918 (1958-12-01), Meyer et al.
patent: 2868740 (1959-01-01), Luce
patent: RE24899 (1960-11-01), Green
patent: 2971916 (1961-02-01), Schleicher et al.
patent: 3016308 (1962-01-01), Macaulay
patent: 3052655 (1962-09-01), Fox et al.
patent: 3057344 (1962-10-01), Abella et al.
patent: 3076790 (1963-02-01), Fox et al.
patent: 3170802 (1965-02-01), Fukushima
patent: 3190837 (1965-06-01), Brynko et al.
patent: 3474777 (1969-10-01), Figge et al.
patent: 3491093 (1970-01-01), Pachter et al.
patent: 3565559 (1971-02-01), Sato
patent: 3567650 (1971-03-01), Bakan
patent: 3574832 (1971-04-01), Engel et al.
patent: 3576758 (1971-04-01), Emrick
patent: 3687926 (1972-08-01), Arima et al.
patent: 3725113 (1973-04-01), Chang
patent: 3748277 (1973-07-01), Wagner
patent: 3794561 (1974-02-01), Matsukawa et al.
patent: 3795739 (1974-03-01), Birkmayer et al.
patent: 3816404 (1974-06-01), Kablaoui et al.
patent: 3822348 (1974-07-01), Higashi et al.
patent: 3849550 (1974-11-01), Teitelbaum
patent: 3933873 (1976-01-01), Love et al.
patent: 3937668 (1976-02-01), Zolle
patent: 3939253 (1976-02-01), Bodor et al.
patent: 3956172 (1976-05-01), Saeki et al.
patent: 3962416 (1976-06-01), Katzen
patent: 3976773 (1976-08-01), Curran
patent: 4035507 (1977-07-01), Bodor et al.
patent: 4048268 (1977-09-01), Ludwig
patent: 4061466 (1977-12-01), Sjoholm et al.
patent: 4117801 (1978-10-01), Dannelly et al.
patent: 4147767 (1979-04-01), Yapel
patent: 4183849 (1980-01-01), Hansen
patent: 4199561 (1980-04-01), Roth et al.
patent: 4217370 (1980-08-01), Rawlings et al.
patent: 4238506 (1980-12-01), Stach et al.
patent: 4239635 (1980-12-01), Rieder
patent: 4239754 (1980-12-01), Sache et al.
patent: 4272506 (1981-06-01), Schwarzberg
patent: 4289759 (1981-09-01), Heavner et al.
patent: 4345588 (1982-08-01), Widder et al.
patent: 4348384 (1982-09-01), Horikoshi et al.
patent: 4351337 (1982-09-01), Sidman
patent: 4352883 (1982-10-01
Darby & Darby
Emisphere Technologies Inc.
Lovering Richard D.
LandOfFree
Method of solubilizing and encapsulating itraconazole does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of solubilizing and encapsulating itraconazole, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of solubilizing and encapsulating itraconazole will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2961904